Companies: 10,795·Total market cap: $144.5T
Applied Therapeutics, Inc.

Applied Therapeutics, Inc.

APLTNASDAQHealthcare
$0.10
+$0.00(+0.00%)
Market Cap$14862969
P/E Ratio
52W High$1.5
52W Low$0.09

Applied Therapeutics, Inc. (APLT) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

aplt · pe ratio · data through Dec 31, 2024

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Applied Therapeutics, Inc. (APLT) measures how much investors pay for each dollar of the company's trailing earnings. APLT's current PE ratio of N/A is calculated by dividing its stock price of $0.10 by its TTM earnings per share of -$0.12.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31

Forward P/E
N/A
FY2026 est. EPS $-0.43
Based on 2 analysts
EPS (TTM)
-$0.12
TTM · diluted EPS
PEG Ratio
-0.01
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Applied Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2017 – 2024 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Applied Therapeutics, Inc.
Applied Therapeutics, Inc.You
APLT
$15MN/A-$0.12
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc.
CRBP
$95MN/A-$5.90
Cardiff Oncology, Inc.
Cardiff Oncology, Inc.
CRDF
$103MN/A-$0.69
Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc.
ELTX
$259MN/A-$2.58
Forte Biosciences, Inc.
Forte Biosciences, Inc.
FBRX
$218MN/A-$0.47
Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc.
MIST
$106MN/A-$0.75
Molecular Partners AG
Molecular Partners AG
MOLN
$148MN/A-$1.65

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2024-12-31Latest
FY2024
$-0.76
2023-12-31
FY2023
$-1.42
2022-12-31
FY2022
$-2.18
2021-12-31
FY2021
$-4.12
2020-12-31
FY2020
$-4.28
2019-12-31
FY2019
$-3.55
2018-12-31
FY2018
$-1.80
2017-12-31
FY2017
$-0.47

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Applied Therapeutics, Inc. (APLT) measures how much investors pay for each dollar of the company's trailing earnings. APLT's current PE ratio of N/A is calculated by dividing its stock price of $0.10 by its TTM earnings per share of -$0.12.

PE Ratio = Stock Price ÷ EPS (TTM)
= $0.10 ÷ -$0.12 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

APLT pe ratio · 6 questions

APLT's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.10 and TTM EPS of -$0.12. Data sourced from Financial Modeling Prep via APLT's SEC 10-K and 10-Q filings.

APLT PE ratioWhat is APLT PE ratioCurrent PE ratio of APLTAPLT PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Applied Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09